Cross-reactive antibody could form basis of broad coronavirus vaccine
Researchers have discovered a cross-reactive coronavirus antibody that could aid in the development of a broad-acting vaccine or treatment.
List view / Grid view
Researchers have discovered a cross-reactive coronavirus antibody that could aid in the development of a broad-acting vaccine or treatment.
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
Researchers have shown that inhalable nanobodies at ultra-low doses can effectively neutralise SARS-CoV-2 in hamsters.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Researchers have explored the interaction between SARS-CoV-2 RNA and the host cell, uncovering possible targets to prevent viral replication.
Tabernanthalog (TBG), similar to the psychedelic drug ibogaine, corrected stress-induced behavioural deficits in mice.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Using computer modelling, a team has shown that a molecular chaperone called GRP78 could be targeted by drugs in strategies to treat COVID-19.
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
Researchers have shown that a protein named aquaporin can disrupt optical development, leading to cataract formation.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.